Title |
Predictors of consent to pharmacogenomics testing in the IDEAL study
|
---|---|
Published in |
Pharmacogenetics and Genomics, November 2013
|
DOI | 10.1097/fpc.0000000000000002 |
Pubmed ID | |
Authors |
Alison B. Jazwinski, Paul J. Clark, Alexander J. Thompson, Stuart C. Gordon, Eric J. Lawitz, Stephanie Noviello, Clifford A. Brass, Lisa D. Pedicone, Janice K. Albrecht, Mark S. Sulkowski, Andrew J. Muir |
Abstract |
Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon and ribavirin for treatment of chronic hepatitis C agreed to provide blood samples for genetic testing. Genome-wide association studies subsequently identified associations between IL28B polymorphism and sustained virologic response, and ITPA polymorphism and ribavirin-associated anemia. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 2% |
Canada | 1 | 2% |
Unknown | 40 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 8 | 19% |
Student > Master | 7 | 17% |
Researcher | 6 | 14% |
Student > Ph. D. Student | 6 | 14% |
Student > Doctoral Student | 2 | 5% |
Other | 3 | 7% |
Unknown | 10 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 29% |
Biochemistry, Genetics and Molecular Biology | 5 | 12% |
Nursing and Health Professions | 3 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
Agricultural and Biological Sciences | 2 | 5% |
Other | 5 | 12% |
Unknown | 12 | 29% |